UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, **SECTION 4(6) AND/OR** UNIFORM LIMITED OFFERING EXEMPTION

OMB APP	ROVAL
OMB NUMBER:	3235-0076
Expires:	May 31, 2005
Estimated average	burden
hours per response	16.00

	SEC USE ONL	Y
Prefix		Serial
ì		1 .
l		1
	Date Received	
İ	1	į

Name of Offering (check if this is ar Offer and sale of Series E Preferred Stock	n amendment and name has changed, and indicate chan	ge.)
Filing Under (Check box(es) that apply):	Rule 504 Rule 505 Rule 506	Section 4(6) DULOE CONTROL
<u> </u>	A. BASIC IDENTIFICATION DATA	JUN 3 0 2004
1. Enter the information requested about the	e issuer	
Name of Issuer (Check if this is an an eNOS Pharmaceuticals, Inc.	nendment and name has changed, and indicate change.	
Address of Executive Offices PO Box 410065, Cambridge, MA 02141	(Number and Street, City, State, Zip Code)	Telephone Number (including Area Code) (800) 386-1768
Address of Principal Business Operations (if different from Executive Offices)	(Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
Brief Description of Business		PROCESSE
Biomedical Technology		JUL 08 2004
Type of Business Organization ⊠ corporation □ business trust	☐ limited partnership, already formed ☐ limited partnership, to be formed	other (please specify):
Actual or Estimated Date of Incorporation of Jurisdiction of Incorporation or Organization	0 6 9	Ear 8 Actual Estimated or State: D E
GENERAL INSTRUCTIONS		
Federal:		
Who Must File: All issuers making an offer	ring of securities in reliance on an exemption under Re	gulation D or Section 4(6), 17 CFR 230,501

et seq. or 15 U.S.C. 77d(6)

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those state that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

-ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. failure to file the appropriate federal notice will not result in a loss of an available state exemption such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENTIFICA	TION DATA		
 Each beneficial owner securities of the issuer 	ssuer, if the issuer h having the power to ;	as been organized within to vote or dispose, or direct	the vote or disposition of,		• •
 Each executive officer Each general and man 		orate issuers and of corporate issuers.	ate general and managing	g partners of par	tnership issuers; and
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	□ Director	General and/or Managing Partner
Full Name (Last name first, if in Cynthia Doerr	dividual)				
Business or Residence Address PO Box 410065, Cambridge, M		er and Street, City, State, Z	ip Code)		
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	☑ Director	General and/or Managing Partner
Full Name (Last name first, if in McNab, Jr., James R.	dividual)				
Business or Residence Address PO Box 410065, Cambridge, M	·	er and Street, City, State, Z	ip Code)		
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if in Klibanov, Alexander	dividual)				
Business or Residence Address	Numbe	er and Street, City, State, Z	in Code)		
PO Box 410065, Cambridge, M					
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	⊠ Director	☐ General and/or Managing Partner
Full Name (Last name first, if in Amir Nashat	dividual)				
Business or Residence Address PO Box 410065, Cambridge, M	•	er and Street, City, State, Z	ip Code)		
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if in Polaris Venture Partners II, L.P.	dividual)				
Business or Residence Address 1000 Winter Street, Suite 3350,	•	er and Street, City, State, Z	ip Code)		*
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	☐ Director	General and/or Managing Partner
Full Name (Last name first, if in Essex Woodlands Health Ventur	•				
Business or Residence Address 100001 Woodloch Forest Drive,	,	er and Street, City, State, Z 77380	ip Code)		
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if in Elan International Services Limi					
Business or Residence Address 102 St. James Court, Flatts, Smir	•	er and Street, City, State, Z FL 04	ip Code)		

		A. BASIC IDENTIFICA	TION DATA		
2. Enter the information request	ed for the following				
 Each promoter of the is 	ssuer, if the issuer h	as been organized within t	he past five years;		
 Each beneficial owner 	having the power to	vote or dispose, or direct	the vote or disposition of	, 10% or more of	f a class of equity
securities of the issuer;					
 Each executive officer 	and director of corp	orate issuers and of corpor	rate general and managing	g partners of part	tnership issuers; and
 Each general and mana 	iging partner of part	nership issuers.			
Check Box(es) that Apply:	Promoter	Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, if inc	dividual)				
Langer, Robert S.					
Business or Residence Address	(Numbe	er and Street, City, State, Z	ip Code)		
PO Box 410065, Cambridge, M.	A 02141				
Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if inc	dividual)				
Polaris Venture Partners II, L.P.					
Business or Residence Address	(Numbe	er and Street, City, State, Z	lip Code)		
1000 Winter Street, Suite 3350,	Waltham, MA 0215	54			
Box(es) that Apply:	☐ Promoter	Beneficial Owner	☐ Executive Officer	Director	☐ General and/or
					Managing Partner
Full Name (Last name first, if inc	Jividual)				
Brigham and Women's Hospital					
					
Business or Residence Address	•	er and Street, City, State, Z	(ip Code)		
1249 Boylston St., Boston, MA	14413				

7-11-120, 131-141 FE - 241-130		der die de		B. INF	ORMATIC	ON ABOU	r offeri	NG			\$ (*10.155.) 166.	
1. Has the is	suer sold, o	or does the i	ssuer intend	i to sell, to	non accredi	ted investo	rs in this of	fering?			Yes	No
			Ans	wer also in	Appendix,	Column 2,	if filing un	der ULOE.				
2. What is th	ie minimun	ı investmen	it that will b	e accepted	from any ir	ndividual?				******	\$ N/A	
				•	•						Yes	No
3. Does the o	offering per	mit joint ov	vnership of	a single un	it?		••••••				\boxtimes	
4. Enter the remuneration agent of a bropersons to be Full Name (LN/A	for solicita oker or deal listed are a	ation of pure er registere associated p	chasers in c d with the S ersons of si	onnection v SEC and/or	with sales o with a state	f securities or states, l	in the offer ist the nam	ing. If a pe e of the bro	rson to be l ker or deale	isted is an er. If more	associate than five	d person or
Business or F	Residence A	Address (Nu	mber and S	treet, City,	State, Zip (Code)						
Name of Asse	ociated Bro	ker or Deal	er						<u> </u>			
States in Whi		Listed Has :										All States
(Check	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
			[NH]		[NM]	[NY]	[NC]	[ND]	[OH]		[OR]	[PA]
[MT] [RI]	[NE] [SC]	[NV] [SD]	[TN]	[NJ] [TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[OK] [WI]	[WY]	[PR]
Business or F	Residence A	Address (Nu	mber and S	treet, City,	State, Zip (Code)					<u>.</u>	
Name of Asse	ociated Bro	ker or Deal	er		<u>. </u>			<u> </u>				
States in Whi										-,		
`		or check ind						IDC1	ret 3			All States
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA] [MN]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[OK]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]		[OR]	[PA]
[RI] Full Name (L	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]
Full Name (L	asi name n	ist, ii maiv	iduai)									
Business or F	Pasidamaa A	ddross (Niv	mhor and C	troot City	State 7in (Code)						
Dusiness of r	cesidence A	rantess (14a	illibel and s	ucei, City,	State, Zip (Jode)						
Name of Asse	ociated Bro	ker or Deal	er	<u> </u>								
States in Whi		Listed Has !										All States
[AL]	[AK]	[AZ]	IIVIGUAI SIA [AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	 [HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C: OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

and already exchanged.	Aggregate	Amount Already
Type of Security	Offering Price	
Debt	\$	
EquitySeries E Preferred Stock	\$ <u>793.440.55</u>	\$ <u>599,999.75</u>
☐ Common ☑ Preferred		
Convertible Securities (including warrants)	\$	\$
Partnership Interests	\$	\$
Other (Specify)	\$	\$
Total	\$ <u>793,440.55</u>	\$ <u>599,999.75</u>
Answer also in Appendix, Column 3, if filing under ULOE.		
2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number Investors	Aggregate Dollar Amoun of Purchases
Accredited Investors	5	\$ <u>599,999.75</u>
Non-accredited Investors	0	\$ <u>0</u>
Total (for filings under Rule 504 only)	N/A	\$N/A
Answer also in Appendix, Column 3, if filing under ULOE.		
3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		
Type of offering	Type of	Dollar Amoun
Rule 505	Security N/A	Sold \$ <u>N/A</u>
Regulation A	N/A	\$_N/A
Rule 504	N/A	\$_N/A
Total	N/A	\$_N/A
4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		V
Transfer Agent's Fees		□ \$ <u>0</u>
Printing and Engraving Costs		\$ 0
Legal Fees		∑ \$ <u>25,000</u>
Accounting Fees		\$ <u>0</u>
Engineering Fees		\$_0
_Sales Commissions (specify finders' fees separately)		\$_0
Other Expenses (identify) Blue Sky Filing Fees, etc.		∑ °\$ <u>1,000</u>
Total		\$ 26,000

	ggregate offering price given in response to Part C - Questi- esponse to Part C - Question 4.a. This difference is the uer."		\$ <u>767,440.55</u>
used for each of the purposes shown. estimate and check the box to the left	usted gross proceeds to the issuer used or proposed to be If the amount for any purpose is not known, furnish an of the estimate. The total of the payments listed must equa uer set forth in response to Part C - Question 4.b above.	Payments Officers Directo Affiliate	rs, & Payments To
			
	stallation of machinery and equipment	<u> </u>	
Acquisition of other businesses (ouildings and facilitiesincluding the value of securities involved in this lange for the assets or securities of another	🗀 \$	D \$
issuer pursuant to a merger)			
• •			🖸 \$
- -		\$	<u></u>
		\$	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	□ \$	
	otals added)		\$767.440.55
Total Payments Listed (Column to			_
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an unconstitutes an unconstitutes and unconstitutes are unconstitutes are unconstitutes.	otals added)	is notice is filed unde	\$767,440.55 r Rule 505, the on, upon written reques
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an under of its staff, the information furnished suer (Print or Type) NOS Pharmaceuticals, Inc.	be signed by the undersigned duly authorized person. If the dertaking by the issuer to furnish to the U.S. Securities and by the issuer to any non-accredited investor pursuant to particular.	tis notice is filed unde Exchange Commissic agraph (b)(2) of Rule	\$767,440.55 r Rule 505, the on, upon written reques
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an under of its staff, the information furnished suer (Print or Type)	be signed by the undersigned duly authorized person. If the dertaking by the issuer to furnish to the U.S. Securities and by the issuer to any non-accredited investor pursuant to particular.	tis notice is filed unde Exchange Commissic agraph (b)(2) of Rule	r Rule 505, the on, upon written reques 502.
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an undof its staff, the information furnished suer (Print or Type) NOS Pharmaceuticals, Inc.	be signed by the undersigned duly authorized person. If the dertaking by the issuer to furnish to the U.S. Securities and by the issuer to any non-accredited investor pursuant to particular.	tis notice is filed unde Exchange Commissic agraph (b)(2) of Rule	r Rule 505, the on, upon written reques 502.
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an under of its staff, the information furnished suer (Print or Type) NOS Pharmaceuticals, Inc. ame of Signer (Print or Type)	be signed by the undersigned duly authorized person. If the dertaking by the issuer to furnish to the U.S. Securities and by the issuer to any non-accredited investor pursuant to particle of Signature Title of Signer (Print or Type)	tis notice is filed unde Exchange Commissic agraph (b)(2) of Rule	r Rule 505, the on, upon written reques 502.
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an undof its staff, the information furnished suer (Print or Type) NOS Pharmaceuticals, Inc. ame of Signer (Print or Type)	be signed by the undersigned duly authorized person. If the dertaking by the issuer to furnish to the U.S. Securities and by the issuer to any non-accredited investor pursuant to particle of Signature Title of Signer (Print or Type)	tis notice is filed unde Exchange Commissic agraph (b)(2) of Rule	r Rule 505, the on, upon written reques 502.
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an undof its staff, the information furnished suer (Print or Type) NOS Pharmaceuticals, Inc. ame of Signer (Print or Type)	be signed by the undersigned duly authorized person. If the dertaking by the issuer to furnish to the U.S. Securities and by the issuer to any non-accredited investor pursuant to particle of Signature Title of Signer (Print or Type)	tis notice is filed unde Exchange Commissic agraph (b)(2) of Rule	r Rule 505, the on, upon written reques 502.
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an unconstitutes an unconstitutes and unconstitutes are unconstitutes are unconstitutes.	be signed by the undersigned duly authorized person. If the dertaking by the issuer to furnish to the U.S. Securities and by the issuer to any non-accredited investor pursuant to particle of Signature Title of Signer (Print or Type)	tis notice is filed unde Exchange Commissic agraph (b)(2) of Rule	r Rule 505, the on, upon written reques 502.
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an undof its staff, the information furnished suer (Print or Type) NOS Pharmaceuticals, Inc.	be signed by the undersigned duly authorized person. If the dertaking by the issuer to furnish to the U.S. Securities and by the issuer to any non-accredited investor pursuant to particle of Signature Title of Signer (Print or Type)	tis notice is filed unde Exchange Commissic agraph (b)(2) of Rule	r Rule 505, the on, upon written reques 502.
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an under of its staff, the information furnished suer (Print or Type) NOS Pharmaceuticals, Inc. ame of Signer (Print or Type)	be signed by the undersigned duly authorized person. If the dertaking by the issuer to furnish to the U.S. Securities and by the issuer to any non-accredited investor pursuant to particle of Signature Title of Signer (Print or Type)	tis notice is filed unde Exchange Commissic agraph (b)(2) of Rule	r Rule 505, the on, upon written reques 502.
Total Payments Listed (Column to the issuer has duly caused this notice to following signature constitutes an under of its staff, the information furnished sucr (Print or Type) NOS Pharmaceuticals, Inc. ame of Signer (Print or Type)	be signed by the undersigned duly authorized person. If the dertaking by the issuer to furnish to the U.S. Securities and by the issuer to any non-accredited investor pursuant to particle of Signature Title of Signer (Print or Type)	tis notice is filed unde Exchange Commissic agraph (b)(2) of Rule	r Rule 505, the on, upon written reques 502.